Review
Published on 26 Oct 2023
IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2023.1239082
- 12,367 views
- 26 citations





